drugset / Trial / NCT01021527

A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

NCT01021527

Phase 1 Completed 12 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverSingle-blindTreatment

Summary

A four-period study to evaluate if the grade glucose infusion procedure will be able to detect an increase in beta-cell glucose sensitivity from exenatide compared to no treatment in healthy subjects.

Timeline

Start
2008-02
Primary completion
2008-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 5 ug Subcutaneous
Subject Exenatide Peptide 10 ug Subcutaneous

Indications

No indication recorded.